Referencias para literatura Línea Cardiometabólica Julio 27 2026

EZETIMIBA: 1. Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025 Nov 7;46(42):4359-4378.

COLESTOX-ROSUVASTATINA: 1. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-2757; 2. Stein EA, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol. 2007;100(9):1387-1396. doi:10.1016/j.amjcard.2007.06.029

RISCOL-ATORVASTATINA: 1. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-2757; 2. Adams SP, et al. Atorvastatin for lowering lipids. Cochrane Database Syst Rev. 2015;(3):CD008226. doi:10.1002/14651858.CD008226.pub3.